Artesunate 60mg powder for solution for injection (with sodium bicarbonate 8.4mg/mL and arginine 20mg/mL injection)

(Guilin Pharmaceutical Co. Ltd), MA168

## WHO Prequalification Programme WHO PUBLIC ASSESSMENT REPORT (WHOPAR)

## [MA168 trade name]\*

Artesunate 60mg powder for injection (with sodium bicarbonate 8.4mg/mL and arginine 20mg/mL injection)

[MA168 trade name], manufactured at Guilin Pharmaceutical Co., Ltd, Guilin, Guangxi, China, was included in the WHO list of prequalified medicinal products for the treatment of malaria on 27 June 2023.

[MA168 trade name] is indicated for malaria treatment. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient of [MA168 trade name] artesunate.

The efficacy and safety of artesunate are well established based on extensive clinical experience in the treatment of malaria.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of artesunate in malaria, the team of assessors advised that [MA168 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [MA168 trade name] in the list of prequalified medicinal products.

## **Summary of prequalification status for [MA168 trade name]:**

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

<sup>\*</sup> Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

Page 1 of 2

(Guilin Pharmaceutical Co. Ltd), MA168

| Initial acceptance   | Date  | Outcome |
|--|---|---------|
| Status on PQ list  | 27 June 2023  | listed  |
| Pharmaceutical quality   | 12 June 2023  | MR      |
| Bioequivalence   | 15 June 2023  | MR      |
| Safety, efficacy   | NA  | NA      |
| GMP (re-)inspection  |   |         |
| API  | 26 September 2021   | MR      |
| FPP  | 19 September 2021   | MR      |
| GCP/GLP (re-)inspection  | NA  | NA      |
| API: active pharmaceutical ingredient FPP: finished pharmaceutical product GCP: good clinical practice [quality standard] GLP: good laboratory practice [quality standard] | GMP: good manufacturing practice [quality standard] MR: meets requirements NA: not applicable, not available PQ: prequalification |         |

The table represents the status of relevant completed activities only.